ПРОДУКТИВНЫЕ КАЧЕСТВА БЫЧКОВ ГЕРЕФОРДСКОЙ ПОРОДЫ РАЗНЫХ СЕЗОНОВ РОЖДЕНИЯ ПРИ ИМПЛАНТАЦИИ ЙОДИСТОГО КАЛИЯ

The paper describes the research in the Altai region on breeding Hereford bulls born in different seasons and application of potassium iodide in order to prevent disturbance in metabolism. The authors explored productive features of Hereford bulls born in autumn and spring in suckling period and further breeding and fattening. The researchers selected 48 similar bulls and divided them into 4 groups: 1st control group and 1st experimental group of bulls born in autumn and implanted with potassium iodide (each group contained 12 animals) and 2nd control group and 2nd experimental group of bulls born in spring and implanted with potassium iodide. On weaning, the animals received “Kaiod” tablets dosed as 12 mg pro animal in the neck subcutaneously. The authors observed that in the same conditions the bulls born in autumn consumed 6.7 % energetic units more. Consumption of digested protein in 1st control, 1st experimental and 2nd control group increased on 28.3, 17.8 and 12.6 % when daily weight gain was 855 g. It differed from other groups on 22.9, 15.6 and 11.7 % correspondently. The researchers observed lower consumption of feeds pro 1 kilo of body weight in the 2nd experimental group on 27.7 and 20.1 % in comparison with the 1st control group and 1st experimental group. The 2nd experimental group (winter bulls) differed on 18 and 10.5 %. The paper shows the lowest costs of 1 hundredweight of weight gain in the 2nd experimental group (on 11 %). The article makes case about the level of profitability, which was higher in the 2nd experimental group on 16.1 % than in the 2nd control one, 32 % higher than in the 1st control group and 22.1 % higher than in the 1st experimental group. В условиях Алтайского края проведены исследования по выращиванию бычков герефордской породы разных сезонов рождения с использованием имплантации йодистого калия с целью предотвращения нарушения обмена веществ. Изучались продуктивные качества бычков герефордской породы осеннего и весеннего сезонов рождения в подсосный период и при последующем доращивании и откорме. Было отобрано 48 бычков-аналогов, которые были разделены на 4 группы по 12 голов: 1-я контрольная и 1-я опытная (с имплантацией йодистого калия) – осеннего рождения, 2-я контрольная и 2-я опытная (с имплантацией йодистого калия) – весеннего рождения. После отъема животным имплантировали таблетки кайод в дозе 12 мг/гол. подкожно в область шеи. Установлено, что при одинаковых условиях содержания и кормления бычки осеннего сезона рождения потребили на 6,7% больше ЭКЕ. Потребление переваримого протеина животными 1-й контрольной, 1-й опытной и 2-й контрольной групп возросло по сравнению со своими аналогами на 28,3; 17,8 и 12,6% соответственно. Данная тенденция наблюдалась при среднесуточном приросте 855 г. Разница по сравнению с другими группами составила 22,9; 15,6 и 11,7% соответственно. Более низкие затраты кормов на 1 кг прироста выявлены во 2-й опытной группе – на 27,7 и 20,1% по сравнению с аналогами 1-й контрольной, 1-й опытной. Отличия по 2-й контрольной (весенний сезон) группе наблюдались на уровне 18,0 и  10,5% соответственно. Наименьшая себестоимость 1 ц прироста отмечена во 2-й опытной группе – по сравнению со 2-й контрольной на 11,0%. Разница между опытными группами сложилась в  пользу бычков 2-й опытной группы  – 12,6%. Уровень рентабельности был выше у бычков 2-й опытной, которая превосходила 2-ю контрольную на 16,1% и бычков 1-й контрольной и 1-й опытной – на 32 и 22,1% соответственно

Electrical and thermal properties of the GaSb-FeGa1.3 eutectic

The electrical conductivity, thermoelectric power, Hall coefficient, and thermal conductivity of the GaSb-FeGa1.3 eutectic were measured in a wide temperature range at different relationships between the directions of the electric current, heat flux, magnetic field, and needlelike metallic inclusions. The results are interpreted in terms of electronic and phonon processes. The metallic inclusions are shown to have a significant effect on the transport properties of the eutectic.NATO ScientificCommittee through the Collaborative Linkage Grant PST.CLGN 97843

Treatment efficacy of arrhythmias and dilated cardiomyopathy syndrome of immune-inflammatory nature using plasmapheresis

Aim. To study the efficacy of plasmapheresis as the main type of pathogenic treatment or in combination with immunosuppressive therapy in patients with dilated cardiomyopathy (DCMP) and arrhythmias of immune-inflammatory nature.Material and methods. The main group included 20 patients with arrhythmic myocarditis (with premature supraventricular / ventricular contraction >3000/day, n=3/8, atrial fibrillation (AF) n=9) and 14 patients with DCMP syndrome (enddiastolic volume (EDV) left ventricle (LV) 6,3±0,6 cm, ejection fraction (EF) 33,5±8,1%). The inclusion criterion was an increase of at least 2 types of anti-cardiac antibodies titers ≥ twice. Myocarditis is diagnosed using myocardial biopsy, magnetic resonance imaging, multispiral computed tomography, scintigraphy, coronary angiography. We used a course of discrete plasmapheresis. The comparison group included 26 patients with an arrhythmic myocarditis and 19 with DCMP syndrome (EDV 6,6±0,8 cm, EF 32,6±7,3%), which plasmapheresis was not used. Dynamics was assessed at 6 and 12 months.Results. In groups of patients with arrhythmias and DCMP, a significant decrease in anti-cardiac antibodies titers was observed immediately after plasmapheresis and in control studies (p<0,05). In patients with arrhythmias, a health-promoting effect (a decrease in the number of premature contraction and a frequency of atrial fibrillation ≥75%) was observed in 65% of the main group and 58% of the comparison group. Predictor of plasmapheresis efficiency was a titer of specific antinuclear factor ≥1: 40 (sensitivity — 92,3%, specificity — 71,4%, AUC — 0,813, p<0,05). Methylprednisolone was prescribed to 45% of patients in the main group and 73% to patients in the comparison group (p>0,05) at a dose of 8 [4; 16] and 16 [10; 24] mg per day, respectively, p>0,05. In patients with DCMP in the main group, a significant increase in EF (p<0,05) (up to 41,4±8,2% and 46,3±12,7% vs 39,1±13,7% and 37,2±10,7% in the comparison group) and the distance of 6-minute walking test was obtained. A good effect (increase in EF by 10% or more) was noted in 50% of the main group and 32% of the comparison group. The predictor of plasmapheresis efficacy was systolic pressure in the pulmonary artery ≥28,5 mm Hg. (sensitivity — 100%, specificity — 71,4%, AUC — 0,893, p<0,05). In the main group, methylprednisolone was assigned to 43% of patients, in the comparison group — 89%, p<0,05. The average doses of methylprednisolone in the main group were significantly lower than in the comparison group (8 [8; 17,25] vs 16 [13; 28] mg per day, p<0,05).Conclusion. Positive clinical response to plasmapheresis was noted in 65% of patients with arrhythmias and in 50% of patients with DCMP of immune-inflammatory nature. In patients with different types of myocarditis, plasmapheresis increases the efficacy of antiarrhythmic and immunosuppressive therapy

High rate of mutations in the BRCA1, BRCA2, CHEK2, NBN, and BLM genes in Russian ovarian cancer patients

Background. The early diagnosis of ovarian cancer (OC) is an important problem in modern gynecological oncology due to significant detection rates for late-stage tumors. Intensive screening of patients from high-risk groups that include OC predisposition gene mutation carriers is indicated.Subjects and methods. An unselected group of 202 patients with OC and two control groups of blood donors: 591 healthy females; 1197 persons (including 591 females, 606 males) were examined. Patients and healthy individuals who identified themselves as ethnic Russians and residents of the Russian Federation participated in the study. Whole peripheral blood samples were collected at the Clinical Subdivisions of the N.N. Blokhin Russian Cancer Research Center and at the Department of Transfusiology of the Acad. B.V. Petrovsky Russian Research Center of Surgery in 2012–2013. Informed consent was obtained from all the participants. DNA was extracted using a Prep-GS-Genetics reagent kit. Real-time polymerase chain reaction genotyping assay was carried out by melting-curve analysis employing an BRCA SNP genotyping kit(BRCA1 and BRCA2 gene mutations) and original oligonucleotides (CHEK2, NBN, and BLM gene mutations). Thirteen population-specific mutations, including 7 (185delAG, 4153delA, 5382insC, 3819delGTAAA, 3875delGTCT, 300T>G, and 2080delA) in the BRCA1 gene, 1 (6174delT) in the BRCA2 gene, 3 (1100delC, IVS2+1G>A, and 470T>C) in the CHEK2 gene, 1 (657delACAAA) in the NBN gene, and 1 (1642C>T) in the BLM gene, were genotyped. Polymerase chain reaction was performed using a DTprime real-time detection thermal cycler.Results and discussion. BRCA1 and BRCA2 gene mutations were detected in 46 (22.8 %) patients with OC; the prevailing mutation in the BRCA1 gene was 5382insC (58.7 %). OC was diagnosed in 32.6 % of the patients aged 51 years or older. The rate of moderate-penetrance mutations (1100delC and IVS2+1G>A in the CHEK2 gene, 657del5 in the NBN gene, and 1642C>T in the BLM gene) was 0.5–1.0 % in the group of OC patients and 0–0.3 % in the control group of healthy women. The majority of these patients (5/6) were diagnosed with OC at age less than 50 years. The CHEK2 mutation, 470T>C, was more frequently encountered in the control group (6.6 %) than in the OC patient group (5.0 %). High rate of the CHEK2 mutation, IVS2+1G>A, was first shown for OC patients in the Russian Federation, the odds ratio was 11.9 (95 % confidence interval, 9.5–14.3; p = 0.056). It was preliminarily concluded that it played an important role in the development of OC in the Russian population; our findings should be verified in further investigations. The difference in the rate of mutations, such as 1100delC, IVS2+1G>A and 470T>C in the CHEK2 gene, 657del5 in the NBN gene, 1642C>T in the BLM gene, were insignificant in the patient and control groups, which may be related to the low population rate of these genetic markers and, in case of the CHEK2 mutation, 470T>C, may be linked to its low penetrance. By taking into account the fact that numerous studies have proven the clinical significance of all examined moderate-penetrance mutations whose prevalence in the Russian population has been confirmed by the authors of this paper, the inclusion of the mutations in a diagnostic panel to detect hereditary predisposition to OC is substantiated. The associated risks are higher for the rare mutations leading to the formation of truncated nonfunctional proteins, which are 1100delC and IVS2+1G>A in the CHEK2 gene, 657del5 in the NBN gene, and 1642C>T in the BLM gene. The penetrance of the CHEK2 mutation, 470T>C, is lower, which should be kept in mind during medical genetic counselling.Conclusion. The total rate of mutations in the BRCA1, BRCA2, CHEK2, NBN, and BLM genes in patients with OC was 30.7 %, which determines the expediency of molecular genetic screening in this category of patients